← FDA DRUG APPROVALS

FDA ANDA · ANDA217495

LEVOTHYROXINE SODIUM

Sponsor: XIROMED

APPLICATION
ANDA217495
TYPE
ANDA
ORIGINAL APPROVAL
2024-11-29
LATEST ACTION
2024-11-29
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

LEVOTHYROXINE SODIUMPrescription
LEVOTHYROXINE SODIUM 100MCG/VIAL · POWDER · INTRAVENOUS

Approval history

2024-11-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →